182 Notes to the company balance sheet UK GAAP G Share capital and share premium account Share Ordinary Shares of 25p each premium Number m m Share capital authorised At 31st December 2008 10,000,000,000 2,500 At 31st December 2009 10,000,000,000 2,500 Share capital issued and fully paid At 1st January 2008 6,012,587,026 1,503 1,266 Issued under share option schemes 5,640,119 2 60 Purchased and cancelled 356,910,908 90 At 31st December 2008 5,661,316,237 1,415 1,326 Issued under share option schemes 3,812,482 1 42 At 31st December 2009 5,665,128,719 1,416 1,368 31st December 31st December 2009 2008 Number 000 of shares issuable under outstanding options 213,110 220,459 Number 000 of unissued shares not under option 4,121,761 4,118,225 At 31st December 2009, of the issued share capital, 117,735,257 shares were held in the ESOP Trust, 474,194,158 shares were held as Treasury shares and 5,073,199,304 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trust are disclosed in Note 33, Employee share schemes.
H Reserves Other Profit and reserves loss account Total m m m At 1st January 2008 1,071 9,287 10,358 Profit attributable to shareholders 8,621 8,621 Dividends to shareholders 2,929 2,929 Ordinary Shares purchased and cancelled 90 3,706 3,616 Capital contribution relating to share based payments 55 55 At 31st December 2008 1,216 11,273 12,489 Profit attributable to shareholders 5,000 5,000 Dividends to shareholders 3,003 3,003 Capital contribution relating to share based payments 39 39 At 31st December 2009 1,255 13,270 14,525 The profit of GlaxoSmithKline plc for the year was 5,000 million 2008 8,621 million, which after dividends of 3,003 million 2008 2,929 million, gave a retained profit of 1,997 million 2008 profit of 5,692 million.
After the cost of shares purchased and cancelled of nil million 2008 3,706 million the profit and loss account reserve at 31st December 2009 stood at 13,270 million 2008 11,273 million, of which 4,096 million is unrealised 2008 4,096 million.
GSK Annual Report 2009 Financial statements P91P182
